In the current study, we identified overexpression of PD-L1 (≥3.0), larger (≥5 cm) tumor size (13), presence of macro-vascular invasion (9, 26, 27) and MVI (28) as predictors of RFS in HCC patients who received adjuvant sorafenib after resection, echoing previous studies. The gene discussed is CD274; the disease is hepatocellular carcinoma.